三個皮匠報告
政策庫
new
付費
搜索

ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗-行業數據

ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗
ZL-1310 預計將持續推進一線/二線 SCLC 以及其他 DLL3 高表達腫瘤的臨床試驗。ZL-1310 針對 2L+ SCLC 單藥臨床試驗已進入劑量優化階段，預計 2025 ASCO上公布數據更新，并于 2025 年啟動關鍵性臨床研究；針對 1L SCLC 聯合治療已進入劑量遞增階段，預計 2025 年內公布數據更新。
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?16KB 圖片尺寸：1735*843
同報告圖片
 / 38
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第1頁
5qC55o2u5oKo5o+Q5L6b55qE5Zu+54mH5YaF5a6577yM5Lul5LiL5piv5o+Q5Y+W55qE5pWw5o2u5Lul5Y+K55Sf5oiQ55qE5pWw5o2u6KGo5qC877yaCgp8IOmhueebriAgICAgICAgICAgICAgICAgICAgICAgICB8IDIwMjXlubTpooTmnJ/lhbPplK7ov5vlsZUgICAgICAgICAgICAgICB8IDIwMjXlubTpooTmnJ/lhbPplK7ov5vlsZUgfCAyMDI25bm06aKE5pyf5YWz6ZSu6L+b5bGVIHwgMjAyN+W5tOmihOacn+WFs+mUrui/m+WxlSB8IDIwMjjlubTpooTmnJ/lhbPplK7ov5vlsZUgfAp8LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyTCtTQ0xDICAgICAgICAgICAgICAgICAgICAgIHwg5Zyo5Yy75a2m5Lya6K6u5LiK5YWs5biD5pWw5o2u5pu05paw77yIMjAyNeW5tOS4iuWNiuW5tO+8iSB8IOWQr+WKqOWFs+mUruaAp+S4tOW6iueglOeptiB8IOWNleiNr+ayu+eWl+WJgumHj+S8mOWMlumYtuautSB8IOWNleiNr+ayu+eWl+WFs+mUruaAp+S4tOW6iueglOeptiB8IOWcqOe+juWbvemAkuS6pOS4iuW4gueUs+ivt++8iOWKoOmAn+aJueWHhu+8iSB8CnwgMUwgU0NMQyAgICAgICAgICAgICAgICAgICAgICB8IOWJgumHj+mAkuWinuaVsOaNruabtOaWsCAgICAgICAgICAgICAgICAgICB8IOiBlOWQiOayu+eWl+WJgumHj+mAkuWinumYtuautSB8IOiBlOWQiOayu+eWl+WJgumHj+S8mOWMlumYtuautSB8IOmaj+iuv+acnyAgICAgICAgICAgICAgfCDogZTlkIjmsrvnlpflhbPplK7mgKfnoJTnqbYgIHwKfCDlhbbku5ZETEwz6KGo6L6+6IK/55ik77yITkVD77yJICAgICAgfCDlkK/liqgx5pyf5Li05bqK56CU56m277yIMjAyNeW5tOS4iuWNiuW5tO+8iSAgIHwgICAgICAgICAgICAgICAgICAgICB8ICAgICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgIHwgICAgICAgICAgICAgICAgICAgICB8Cnwg5YW25LuWICAgICAgICAgICAgICAgICAgICAgICAgIHwg56+u5byP56CU56m2ICAgICAgICAgICAgICAgICAgICAgICAgICB8ICAgICAgICAgICAgICAgICAgICAgfCAgICAgICAgICAgICAgICAgICAgIHwg5Y2V6IeC5YWz6ZSu5oCn56CU56m2ICAgICAgfCAgICAgICAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWGjem8juWMu+iNr+WFrOWRig==
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第2頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第3頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第4頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第5頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第6頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第7頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第8頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第9頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第10頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第11頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第12頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第13頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第14頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第15頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第16頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第17頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第18頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第19頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第20頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第21頁
55Sx5LqO5Zu+54mH5YaF5a656L6D5aSa77yM5oiR5bCG5YiG5aSa5qyh5o+Q5Y+W44CC5Lul5LiL5piv56ys5LiA5qyh5o+Q5Y+W55qE5YaF5a6577yaCgp8IOWbvjLvvJrlub/ms5vmnJ/lsI/nu4bog57ogrrnmYzljaDmr5TnuqY3NSXvvIzlvoDlvoDkvp3otZbns7vnu5/mgKfmsrvnlpfvvIzpooTlkI7mlbTkvZPovoPlt64gfAp8LS0tfAp8IHwgMjUl5bGA6ZmQ5pyfIChMUykgfCA3NSXlub/ms5vmnJ8gKEVTKSB8CnwgfCBJLUlJ5pyfIChUIGFueSwgTiBhbnksIE1PKSB8IElW5pyfIChUIGFueSwgTiBhbnksIE0xYS9iL2MpIHwKfCB8IOWPr+S7peWuieWFqOS9v+eUqOagueayu+aAp+eahOaUvueWl+WJgumHj+OAguaOkumZpFQzLTTnlLHkuo7ogrrpg6jlpJrlj5Hnu5PoioLmiJbogIXogr/nmKQv57uT6IqC5L2T56ev6L+H5aSn6ICM5LiN6IO96KKr5YyF5ZCr5Zyo5LiA5Liq5Y+v6ICQ5Y+X55qE5pS+55aX6K6h5YiS5Lit44CCIHwg5oiW6ICFVDMtNOeUseS6juiCuumDqOWkmuWPkee7k+iKguaIluiAheiCv+eYpC/nu5PoioLkvZPnp6/ov4flpKfogIzkuI3og73ooqvljIXlkKvlnKjkuIDkuKrlj6/ogJDlj5fnmoTmlL7nlpforqHliJLkuK3jgIIgfAoK6LWE5paZ5p2l5rqQ77ya6Zi/5pav5Yip5bq35YWs5ZGK
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第22頁
fCDkuI3oia/lj43lupQgfCDmgqPogIUobj0yNCkgfCDlj5HnlJ/njocoJSkgfAp8IC0tLSB8IC0tLSB8IC0tLSB8CnwgVFJBRSAo4omlMjAlKSB8ICB8ICB8Cnwg5Y+R54OnIHwgMTcgfCA3MC44JSB8Cnwg6LSr6KGAIHwgMTEgfCA0NS44JSB8CnwgQ1JTIHwgMTEgfCA0NS44JSB8Cnwg55m957uG6IOe6K6h5pWw5LiL6ZmNIHwgMTAgfCA0MS43JSB8Cnwg5LmP5YqbIHwgOCB8IDMzLjMlIHwKfCDkuJnmsKjphbjmsKjln7rovaznp7vphbbljYfpq5ggfCA4IHwgMzMuMyUgfAp8IOaBtuW/gyB8IDggfCAzMy4zJSB8Cnwg5L2O55m96JuL55m96KGA55eHIHwgNyB8IDI5LjIlIHwKfCDohbnms7sgfCA3IHwgMjkuMiUgfAp8IOS4reaAp+eykue7huiDnuiuoeaVsOmZjeS9jiB8IDcgfCAyOS4yJSB8Cnwg5L6/56eYIHwgNiB8IDI1LjAlIHwKfCDpo5/mrLLkuIvpmY0gfCA1IHwgMjAuOCUgfAp8IOWRleWQkCB8IDUgfCAyMC44JSB8Cnwg5L2O6ZKg6KGA55eHIHwgNSB8IDIwLjglIHwKfCAz57qn5Lul5LiKIFRSQUUgfCAgfCAgfAp8IOa3i+W3tOe7huiDnuiuoeaVsOS4i+mZjSB8IDIgfCA4LjMlIHwKfCDkuK3mgKfnspLnu4bog57orqHmlbDpmY3kvY4gfCAxIHwgNC4yJSB8Cnwg6Jma5byxIHwgMSB8IDQuMiUgfAp8IENSUyB8IDEgfCA0LjIlIHwKCui1hOaWmeadpea6kO+8muazveeSn+WItuiNr+WFrOWRig==
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第23頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第24頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第25頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第26頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第27頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第28頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第29頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第30頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第31頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第32頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第33頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第34頁
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第35頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第36頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第37頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第38頁
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
ZL-1310預計將持續一線/二線SCLC以及其他DLL3高表達腫瘤的臨床試驗_第39頁
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
所屬報告： 生物制品行業深度報告：小細胞肺癌中國管線全球領先研發聚焦三大新領域-250512（35頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站